Phase 2 N=19 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
Kaposi's Sarcoma · HIV Infections · HIV Seronegativity
Primary: Response Rate — 31 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
Phase 2 N=38 A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
Bronchiectasis
Primary: Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline — 1.08; 1.01 ratio
Phase 2 N=56 A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Ratio of Sputum Absolute Neutrophil Count at End of Treatment Compared to Baseline — 1.07; 1.10 ratio
Phase 2 N=52 Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease (COPD)
Primary: AWT-Pi10 (Airway Wall Thickness of a Theoretical Airway With an Internal Perimeter of 10 mm) — 3.84; 3.83 mm
Phase 2 N=191 Study Effect of VIA-2291 on Vascular Inflammation
Coronary Artery Disease
Primary: Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood — -88126; -95703; -122668; -20843 pg/mL — p=<0.001
Phase 2 N=407 Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter — 72; 75; 65; 66 Subjects
Phase 2 N=388 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). — 66; 66; 69; 73…
Phase 2 N=1,103 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL) — 255; 76 Participants
Phase 2 N=102 BMS 247550 to Treat Kidney Cancer
Renal Cell Carcinoma
Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants
Phase 2 N=50 Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy
Atherosclerosis
Primary: Percent Cross-sectional Area of Macrophages in Plaque Tissue — 8.08; 8.19 Percent Area — p=0.97
Phase 2 N=33 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass Graft · Cardiopulmonary Bypass
Primary: Incidence of Adverse Events — 3; 3; 5; 4 participants
Phase 2 N=72 Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Primary: Overall Survival — 21 months
Phase 2 N=95 Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months — 8; 7 Participants
Phase 2 N=195 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
Leukemia, Acute Myeloid · Myelodysplastic Syndrome
Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants